Increase of toll-like receptor 4 but decrease of interleukin-8 mRNA expression among ischemic stroke patients under aspirin treatment

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1316-1319

  Wu, Dean ^a,c   Sheu, Jehn Shing ^b,c   Liu, Hsing Cheng ^b,d   Yuan, Rey Yue ^e   Yu, Jia Ming ^e   Sheu, Jau Jiuan ^e   Hung, Chia Hsiu ^f   Hu, Chaur Jong ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aspirin; Interleukin 8; Ischemic stroke; MRNA; Toll like receptors

Indexed keywords

ACETYLSALICYLIC ACID; COMPLEMENTARY DNA; INTERLEUKIN 8; MESSENGER RNA; RNA; TOLL LIKE RECEPTOR 4;

AGED; ARTICLE; ATHEROGENESIS; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TISSUE INJURY;

AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4;

EID: 84868300236     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.022     Document Type: Article

References (39)

1. Bradley W.G. Neurology in clinical practice 2004, Butterworth-Heinemann, Philadelphia.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
3. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192.
4. Kopp E.B., Medzhitov R. The toll-receptor family and control of innate immunity. Curr Opin Immunol 1999, 11:13-18.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
6. Vink A., Schoneveld A.H., van der Meer J.J., van Middelaar B.J., Sluijter J.P., Smeets M.B., et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002, 106:1985-1990.
7. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 1999, 147:213-225.
8. Yang Y.Y., Hu C.J., Chang S.M., Tai T.Y., Leu S.J. Aspirin inhibits monocyte chemoattractant protein-1 and interleukin-8 expression in TNF-alpha stimulated human umbilical vein endothelial cells. Atherosclerosis 2004, 174:207-213.
9. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
10. Marsh B.J., Williams-Karnesky R.L., Stenzel-Poore M.P. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009, 158:1007-1020.
11. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized ldl. Circulation 2001, 104:3103-3108.
12. Pasterkamp G., Van Keulen J.K., De Kleijn D.P. Role of toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004, 34:328-334.
13. Curtiss L.K., Tobias P.S. The toll of toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets 2007, 8:1230-1238.
14. Caso J.R., Pradillo J.M., Hurtado O., Lorenzo P., Moro M.A., Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608.
15. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002, 195:99-111.
16. Beutler B. Innate immune responses to microbial poisons: discovery and function of the toll-like receptors. Annu Rev Pharmacol Toxicol 2003, 43:609-628.
17. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999, 274:10689-10692.
18. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., et al. The extra domain a of fibronectin activates toll-like receptor 4. J Biol Chem 2001, 276:10229-10233.
19. Ohashi K., Burkart V., Flohe S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000, 164:558-561.
20. Sasu S., LaVerda D., Qureshi N., Golenbock D.T., Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001, 89:244-250.
21. Leinonen M., Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002, 2:11-17.
22. Kalayoglu M.V., Libby P., Byrne G.I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002, 288:2724-2731.
23. Beutler B., Beutler E. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:1978-1980. author reply 1978-80.
24. Yang I.A., Holloway J.W., Ye S. Tlr4 asp299gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003, 170:187-190.
25. Ameziane N., Beillat T., Verpillat P., Chollet-Martin S., Aumont M.C., Seknadji P., et al. Association of the toll-like receptor 4 gene asp299gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003, 23:e61-e64.
26. Boekholdt S.M., Agema W.R., Peters R.J., Zwinderman A.H., van der Wall E.E., Reitsma P.H., et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003, 107:2416-2421.
27. Lin Y.C., Chang Y.M., Yu J.M., Yen J.H., Chang J.G., Hu C.J. Toll-like receptor 4 gene c119a but not asp299gly polymorphism is associated with ischemic stroke among ethnic chinese in taiwan. Atherosclerosis 2005, 180:305-309.
28. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
29. Liu X., Ukai T., Yumoto H., Davey M., Goswami S., Gibson F.C., et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008, 196:146-154.
30. Kuwahata S., Fujita S., Orihara K., Hamasaki S., Oba R., Hirai H., et al. High expression level of toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis 2010, 209:248-254.
31. Reismann P., Lichy C., Rudofsky G., Humpert P.M., Genius J., Si T.D., et al. Lack of association between polymorphisms of the toll-like receptor 4 gene and cerebral ischemia. J Neurol 2004, 251:853-858.
32. Barr T.L., Conley Y., Ding J., Dillman A., Warach S., Singleton A., et al. Genomic biomarkers and cellular pathways of ischemic stroke by rna gene expression profiling. Neurology 2010, 75:1009-1014.
33. Ferronato S., Lira M.G., Olivato S., Scuro A., Veraldi G.F., Romanelli M.G., et al. Upregulated expression of toll-like receptor 4 in peripheral blood of ischaemic stroke patients correlates with cyclooxygenase 2 expression. Eur J Vasc Endovasc Surg 2010, 1-6.
34. Hung C.H., Wu D., Lin F.Y., Yuan R.Y., Hu C.J. Toll-like receptor 4 and vcam-1 in monocyte-endothelium adhesion induced by lipopolysaccharide. J Exp Clin Med 2010, 2:297-301.
35. AH Ahmed C.-J.H., Paczynski R., Hsu C.Y. Pathophysiology of ischemic injury. Stroke therapy 2001, Butterworth-Heinemann. M. Fisher (Ed.).
36. Fan J., Kapus A., Marsden P.A., Li Y.H., Oreopoulos G., Marshall J.C., et al. Regulation of toll-like receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharide. J Immunol 2002, 168:5252-5259.
37. Brea D., Blanco M., Ramos-Cabrer P., Moldes O., Arias S., Perez-Mato M., et al. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J Cereb Blood Flow Metab 2011, 1-8.
38. Domac F.M., Misirli H. The role of neutrophils and interleukin-8 in acute ischemic stroke. Neurosciences (Riyadh) Apr. 2008, 13(2):136-141.
39. Heidi O., Hans C.D.A., Niels L.S., Karl-Friedrich A., Leif S. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol Apr. 2011, 258(4):677-685.